iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
iPS細胞技術を用いた代表的な神経変性疾患に対する病態モデリングと創薬研究に関する最新の知見を総説としてまとめました。
Abstract: It has been 15 years since the birth of human induced pluripotent stem cell (iPSC) technology in 2007, and the scope of its application has been expanding. In addition to the development of cell therapies using iPSC-derived cells, pathological analyses using disease-specific iPSCs and clinical trials to confirm the safety and efficacy of drugs developed using iPSCs are progressing. With the innovation of related technologies, iPSC applications are about to enter a new stage. This review outlines advances in iPSC modeling and therapeutic development for cardinal neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinson’s disease, and Alzheimer’s disease.
Author: Hideyuki Okano, Satoru Morimoto
Journal: Cell Stem Cell 2022;29(2):189-208.
投稿者プロフィール

- Project Associate Professor
-
Satoru Morimoto, M.D., Ph.D.
Keio University Regenerative Medicine Research Center (KRM)
Project associate professorResearch Gate Building TONOMACHI 2, 4B, 3-25-10, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa,
210-0821, Japan
最新の投稿
令和6年度(FY2024)2024.12.24Swift induction of human spinal lower motor neurons and robust ALS cell screening via single-cell imaging
令和6年度(FY2024)2024.09.24Multiple lines of evidence for disruption of nuclear lamina and nucleoporins in FUS amyotrophic lateral sclerosis
令和6年度(FY2024)2024.09.16Spinal cord motor neuron phenotypes and polygenic risk scores in sporadic amyotrophic lateral sclerosis: deciphering the disease pathology and therapeutic potential of ropinirole hydrochloride
令和6年度(FY2024)2024.08.19Proteomic insights into extracellular vesicles in ALS for therapeutic potential of Ropinirole and biomarker discovery